

Major biopharmaceutical deals for genOway in first quarter of 2009

Lyon, France - May 14th 2009 - genOway (ALTERNEXT-NYSE:ALGEN) reports the expansion of its business with major biopharmaceutical companies. This growing business demonstrates the quality and accuracy of genOway's StemCellHY technology platform.

The company provides customized, genetically modified rodents such as inducible and conditional knockouts, humanized models for Discovery, Preclinical, Pharmacology and DMPK departments.

The main achievements of this first quarter of 2009 are:

- Initial 2 Millions USD deal with a top 10 biopharmaceutical company has already been surpassed by 50% in Q1 2009. Additional business will be signed in the second quarter of 2009.
- Renewal of a 2 year master service agreement (1.2 MUSD achieved in previous agreement) with a top 10 biopharmaceutical company.

genOway's platform is providing customers with unparalleled value in the industry:

- Shorter development times than competitors as a result of automatized production units, accurate model design and use of new stem cells lines from the StemCellHY platform
- Innovative models anticipating needs of animal models for following steps of the drug development program
- Development of models enabling better predictability of human pharmacology
- Strong customer support at each step of development: accurate project design and clear identification of risk factors, regular and detailed customer updates on the project's development and support for model validation and readiness.

The company is expanding its portfolio of catalog models in immunology (cytokines reporter models, HLA and IgE-IgER humanized models), ADME – DMPK (CYPs, transporters) but also in metabolic disorders (ZNT8 KO and conditional KO model), pain (OPRL1 – Neuroceptin KO rat), neurosciences (SERT KO rat) and genetic tools (Cre & Flp lines).

- new pharmaceutical companies are using genOway's catalog models in this first quarter of 2009.

“The growth of our biopharmaceutical business is the demonstration that our technologies are fulfilling industry expectation on both innovation and reliability. Current customer satisfaction combined with our innovative technologies and our outstanding production units is boosting our customer portfolio of pharmaceutical companies.”

said Alexandre Fraichard, CEO of genOway.

For more information, please contact:

For business opportunities: Kader Thiam, VP Transgenic Technologies

For press relations: Marie Norbert, communications department

Email: info@genoway.com / Tel : +33 (0)4 37 65 41 00



About genOway

genOway (ALTERNEXT-NYSE:ALGEN) is a biotechnology company dedicated to the development of genetically modified animal models aimed at enhancing the reliability and relevancy of in vivo research projects. Focusing its efforts on the mouse and rat, genOway's expertise comprises transgenic technologies such as pronuclear microinjection, knock-out, knock-in, knock-down, point mutation and humanization combined with innovative patented technologies adapted to target validation, in vivo drug screening as well as drug efficacy and safety trials. Collaborations with world leaders (Charles River Laboratories, Invitrogen, Tet systems, etc.) enable genOway to provide its customer with a complete portfolio of products and services for all aspects of model generation and characterization. Operating in 22 countries in Europe, North America and Asia, genOway has developed rat and mouse lines for 55 companies and 190 research institutions. Thanks to its industrialized production facilities, genOway is involved in large-scale projects with several academic centers (German National Genome Research Network, University College London, King's College London, Max Planck Institute) and with pharmaceutical companies (BayerCorp, Boehringer Ingelheim, Johnson & Johnson).

For more information consult: www.genoway.com